|1.||Huckriede, Anke: 4 articles (02/2014 - 03/2011)|
|2.||Liu, Heng: 4 articles (02/2014 - 03/2011)|
|3.||Wilschut, Jan: 4 articles (02/2014 - 03/2011)|
|4.||Karanam, Balasubramanyam: 3 articles (01/2015 - 02/2009)|
|5.||Roden, Richard B S: 3 articles (01/2015 - 02/2009)|
|6.||de Vries-Idema, Jacqueline: 3 articles (02/2014 - 01/2012)|
|7.||Peng, Shiwen: 2 articles (01/2015 - 02/2009)|
|8.||Patil, Harshad P: 2 articles (01/2013 - 01/2012)|
|9.||Ragupathi, Govind: 2 articles (09/2009 - 05/2005)|
|10.||Gambhira, Ratish: 2 articles (06/2009 - 02/2009)|
|1.||Human Influenza (Influenza)
02/01/2014 - "We earlier showed that GPI-0100, a semi-synthetic saponin derivative with amphiphilic structure, significantly stimulates the immunogenicity and protective efficacy of influenza subunit vaccine administered via a systemic route. "
01/01/2012 - "Enhancement of the immunogenicity and protective efficacy of a mucosal influenza subunit vaccine by the saponin adjuvant GPI-0100."
01/01/2013 - "The study was conducted in BALB/c mice and the vaccine formulation was an influenza subunit vaccine supplemented with GPI-0100, a saponin-derived adjuvant. "
01/01/2012 - "Here, we used a murine challenge model to evaluate the adjuvant activity of GPI-0100, a saponin-derived adjuvant, on influenza subunit vaccine administered via the intranasal or the intrapulmonary route. "
03/03/2011 - "Here we used a murine challenge model to evaluate the potential of GPI-0100, a semi-synthetic saponin derivative, to serve as a dose-sparing adjuvant for influenza subunit vaccine. "
03/06/2006 - "Genital HSV-2 infections in guinea pigs were also utilized to determine if gD combined with GPI-0100 was protective against infection, disease severity and viral shedding. "
03/06/2006 - "The results obtained in a genital HSV-2 infection of guinea pigs did not indicate enhanced protection or reduced virus shedding following immunization with GPI-0100 and gD. "
03/06/2006 - "Guinea pigs immunized with HSV-1 gD with or without GPI-0100 had significantly reduced area under the curve lesion scores, but infection rates and virus shedding was not altered. "
11/01/2008 - "These studies were performed to determine the effect of AD-472, an attenuated human herpes simplex virus (HSV) type 2 or HSV-2 glycoprotein D (gD) when combined with an adjuvant, GPI-0100, a semi-synthetic Quillaja Saponin analog in a genital HSV-2 infection in guinea pigs. "
11/01/2008 - "Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs."
|3.||Prostatic Neoplasms (Prostate Cancer)
05/02/2005 - "Two batches of GPI-0100 (the second with higher purity) were tested with doses ranging between 100 and 5000 microg in groups of five treated prostate cancer patients who had no evidence of disease except for rising PSA levels. "
05/02/2005 - "A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21."
02/11/2009 - "Vaccination with TA-CIN in GPI-0100 also completely prevented tumor growth after challenge with 5x10(4) HPV16-transformed TC-1 tumor cells, whereas vaccination with TA-CIN alone delayed tumor growth. "
01/01/2015 - "Thus formulation of TA-CIN with GPI-0100 and intra-tumoral delivery after cisplatin treatment elicits potent therapeutic responses in a murine model of HPV16+ cancer. "
01/01/2015 - "Injection of TA-CIN alone, but not GPI-0100, into the tumor (i.t.) was similarly efficacious after cisplatin therapy, but the mice eventually succumbed. "
01/01/2015 - "Here we sought to optimize both the immunogenicity of TA-CIN via formulation with GPI-0100 and treatment of HPV16+ cancer by vaccination after cisplatin chemotherapy. "
01/01/2015 - "Sequential cisplatin therapy and vaccination with HPV16 E6E7L2 fusion protein in saponin adjuvant GPI-0100 for the treatment of a model HPV16+ cancer."
|2.||QS 21 (QS21)
|4.||Immunologic Adjuvants (Immunologic Adjuvant)
|5.||globo H-keyhole limpet hemocyanin QS-21 vaccine
|6.||glycoprotein D-herpes simplex virus type 2
|1.||Drug Therapy (Chemotherapy)